pSivida (NSDQ:PSDV) has submitted a new drug application to the FDA for its Durasert implant that provides three years of treatment for people with posterior segment uveitis.
The drug-delivery product’s NDA includes data from two Phase III trials, both of which met their primary efficacy endpoints after six months.
Get the full story at our sister site, Drug Delivery Business News.
The post pSivida seeks FDA nod for 3-year treatment of posterior segment uveitis appeared first on MassDevice.
from MassDevice http://ift.tt/2mdym4t
Cap comentari:
Publica un comentari a l'entrada